Researchers speaking anonymously to the Post said that the research could be successful, but Hasenkrug’s request has not been granted because of a federal moratorium on NIH research involving fetal tissue from elective abortions.
A spokesperson for the Department of Health and Human Services (HHS) told CNA on Thursday that, regarding Hasenkrug’s particular request, “no decision has been made.”
The administration “has activated a whole-of-government, whole-of-America approach to prepare for and respond to COVID-19,” the HHS spokesperson said, including “kick-starting the development of vaccines and therapeutics through every possible avenue.”
The federal moratorium on aborted fetal tissue research was first announced in June, 2019, when HHS halted new NIH research with aborted fetal tissue and limited funding of “extramural” research on aborted fetal tissue, or tests conducted outside the NIH.
“Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trump’s administration,” HHS stated in the 2019 announcement.
In addition, the administration said that federal funding of extra research would be subject to federal ethics advisory boards, and applicants would have to provide a justification for their research on fetal tissue.
The coronavirus pandemic has killed more than 10,000 people worldwide. There were more than 14,000 confirmed COVID-19 cases in the U.S. as of Friday morning, although some scientists say the number is likely much higher due to lack of widespread testing.
Despite some claims that restrictions on aborted fetal tissue research could cost lives during a pandemic, a bioethicist and a professor of molecular genetics both cautioned that Hansenkrug’s proposal is no guarantee of COVID-19 treatments or a vaccine.
“There’s a lot of ‘maybes’ along the line,” Dr. David Prentice, vice president and research director for the Charlotte Lozier Institute and an adjunct professor of molecular genetics at the Pontifical John Paul II Institute in Washington, D.C., told CNA. “It’s a totally unproven, unvalidated technology.”
Researchers would have to successfully implant fetal lung tissue in mice, confirm that mice can be infected, and then test for treatments of the new coronavirus.
There are ethical alternatives to fetal tissue research, Prentice and Brehany said.
“People are working on other ways of curing the sickness brought on by this virus,” Brehany said. “There are some ideas out there.”
Subscribe to our daily newsletter
At Catholic News Agency, our team is committed to reporting the truth with courage, integrity, and fidelity to our faith. We provide news about the Church and the world, as seen through the teachings of the Catholic Church. When you subscribe to the CNA UPDATE, we'll send you a daily email with links to the news you need and, occasionally, breaking news.
As part of this free service you may receive occasional offers from us at EWTN News and EWTN. We won't rent or sell your information, and you can unsubscribe at any time.
“In other words, should we conclude that perhaps we’re all going to die, or many people will die, because of this restriction? And honestly, I think the short answer is ‘no’,” he said.
Clinical trials are almost underway on “humanized mice” with human genes, to develop antibodies to the coronavirus infection, Prentice said. A French study found that a combination of the anti-malarial drug hydroxychloroquine with the antibiotic azithromycin helped reduce the duration of the new coronavirus.
Another study found that the transplantation of mesenchymal stem cells (MSCs) in patients in a Beijing hospital with severe COVID-19 pneumonia helped significantly improve their lung condition within two days.
Brehany said the current pandemic should not necessitate the removal of existing ethical standards.
“Even as we try to grapple with this pandemic,” he said, “survival at all costs, including the costs of acting in an unethical manner, is not right.”
The timing of the researchers’ complaints is conspicuous, Prentice said, as HHS announced on Feb. 20 that it was establishing a Human Fetal Tissue Research Ethics Advisory Board to review grant applications for aborted fetal tissue research, and would be accepting nominations within 30 days.